In this Blog, a strong case is being made for improving Finnish science policies and to initiate communations between leading reseachers and ministry representatives
Globally, drug development and health technologies are among the most rapidly growing business fields. Also in Finland, the two biggest pharma companies, Bayer and Orion have been among the biggest tax payers for years and health technologies constitutes the most profitable line of business related to exports of high-end technologies. In order to support the further growth of the field, Finnish government established a growth strategy for health technologies some years ago, but its implementation has been very slow and funding very marginal. However, at the same time the government has made significant investments to the mining, ICT, and technology-related research. In the accompanied video Professor Jukka Westermarck (Turku Bioscience Centre) and Marco Hautalahti (Director of National Biobanks), discuss the questions why government does not see health technologies as profit-making opportunities, and how big a problem is the underfunding of the growth strategy of health technologies? The panel discussion was held as part of “Mediuutiset” (Medical News) webinar Dec, 15, 2020 “How do centers of excellence change healthcare?”